Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

Q2 2023 YUPELRI® (revefenacin) net sales of $55.0 million, recognized by Viatris, up 12% from Q2 20221 Q2 2023 YUPELRI total retail TRx and new to product TRx...

Related Keywords

United Kingdom ,Dublin ,Ireland ,Ricke Winningham ,Theravance Biopharma ,Company Form ,Prnewswire Theravance Biopharma Inc ,Symphony Health ,Theravance Biopharma Inc ,While Viatris Inc ,Securities Exchange ,Company Annual Report On Form ,Development Rd Expenses ,Chief Executive ,Royalty Pharma ,Based Compensation ,Related Expenses ,Live Webcast Today ,Private Securities Litigation Reform Act ,Securities Exchange Act ,Net Sales ,Annual Report ,Months Ended June ,While Viatris ,Nc ,